

# **Effect of Statin therapy on Erythropoietin Response in Prevelant Haemodialysis Patients**

*Thesis*

*By*

*Samer Magdy Hassan Aly  
M.B.B.Ch*

*Submitted for Partial Fulfillment of  
Master Degree in Internal Medicine*

*Supervised by*

**Dr. Khaled Hussien Abou Seif**

*Professor of Internal Medicine and Nephrology  
Faculty of Medicine Ain Shams University*

**Dr. Aber Halim Baki**

*Lecturer of Internal Medicine and nephrology  
Faculty of Medicine Ain Shams University*

**Dr. Ahmed Shaaban Serag El Deen**

*Lecturer of Internal Medicine and Nephrology  
Faculty of Medicine Ain Shams University*

**Faculty of Medicine  
Ain Shams University**

**2012**



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا إِنَّكَ  
أَنْتَ الْعَلِيمُ الْحَكِيمُ

( )





## Acknowledgement

*First and foremost, thanks to **Allah** for giving me the will and the patience to finish this work,  
First and foremost, I'd like to thank Allah, the most kind and the most merciful.*

*I would like to express my sincere gratitude to **Prof. Dr. Khaled Hussien Abo Seif** Professor of Internal Medicine and nephrology Faculty of Medicine, Ain Shams University, for his kind supervision and guidance. It's great honor to work under his supervision.*

*My heartiest thanks to **Dr. Aber Halimbaki** Lecturer of Internal Medicine and nephrology, Faculty of Medicine, Ain Shams University, whose encouragement, expert guidance and support from the initial to the final level of this work,*

*My deepest gratitude and my sincere thanks to **Dr. Ahmed Shaaban Serag El Deen** Lecturer of Internal Medicine and nephrology Faculty of Medicine, Ain Shams University, for his kind supervision and support to end this work,*

*I would like to thank all the Staff Members of internal medicine and nephrology department in maadimitirian hospital, and all those who helped me and facilitated the whole procedures to accomplish this work,*

*Finally, an honorable mention goes to **my family** for their support to complete this project.*

---



**Samer Magdy Hassan Aly**

# Contents

List of Abbreviations .....	I
List of Tables .....	III
List of Figures .....	V
<b>Introduction and Aim of the Work .....</b>	<b>1</b>
<b>Review of literature.....</b>	<b>4</b>
* Chapter 1: Anemia in CKD and Role of Erythropoietin...	4
* Chapter 2: Dyslipidemia of CKD and Role of Statin .....	32
<b>Subjects and Methods.....</b>	<b>71</b>
<b>Results .....</b>	<b>81</b>
<b>Discussion.....</b>	<b>95</b>
<b>Summary .....</b>	<b>106</b>
<b>Conclusion.....</b>	<b>109</b>
<b>References .....</b>	<b>110</b>
<b>Arabic Summary .....</b>	<b>--</b>

---

## List of Abbreviations

---

ACAT	:	Acyl-CoA cholesterol acyltransferase
ACE-I	:	Angiotensin converting enzyme inhibitors
AIDS	:	Acquired Immunodeficiency Syndrome
AIHA	:	Autoimmune hemolytic anemia
APOA	:	Apolipoprotein A
APOB	:	Apolipoprotein B
ARBs	:	Angiotensin receptor blockers
BFU-E	:	burst forming units erythroid
CHr	:	Content of Hb in reticulocytes
CFU-E	:	Colony-forming units-erythroid
CKD	:	Chronic kidney disease
CRF	:	Chronic renal failure
CRP	:	C-reactive protein
CVD	:	Cardiovascular disease
CYP3A4	:	Cytochrome P450 3A4
DPO	:	Darbepoetin alfa
eNOS	:	Endothelial nitric oxide synthase
EPO	:	Erythropoietin
ESAs	:	erythropoiesis stimulating rate
ESR	:	Erythrocyte sedimentation rate
ESRD	:	End stage renal disease
FPP	:	Farnesyl pyrophosphate
GFR	:	Glomerular filtration rate
GATA2	:	GATA binding protein 2
GGPP	:	Geranylgeranyl pyrophosphate
GTPases	:	Guanosinetriphosphatases
Hb	:	Hemoglobin
Hct	:	Hematocrite
HD	:	Hemodialysis
HDL	:	High-density lipoprotein

HF	:	Heart failure
HMG-CoA	:	3-Hydroxyl-3-methylglutaryl coenzyme A
ICAM-1	:	Intercellular Adhesion Molecule 1
IL	:	Interleukins
LCAT	:	Lecithin-cholesterol acyltransferase
LDL	:	Low-density lipoprotein
LMW	:	Low molecular weight
LVH	:	left ventricular hypertrophy
MCP-1	:	Monocyte chemotactic protein-1
NKF	:	National kidney foundation
NF $\kappa$ B	:	Nuclear factor kappa B
PTH	:	Parathyroid hormone
QOL	:	Quality of life
RAS	:	Renin angiotensin system
RHUP	:	Recombinant human erythropoietin
TIBC	:	Total iron binding capacity
TGS	:	Triglycerides
TSAT	:	Transferrin saturation
TGF $\beta$	:	Transforming growth factor $\beta$
TNF $\beta$	:	Tumor necrosis factor $\beta$
SLE	:	Systemic lupus erythematosus
VCAM-1	:	vascular cell adhesion molecule 1
VLDL	:	Very Low-density lipoprotein

## List of tables

<i><b>Table</b></i>	<i><b>Title</b></i>	<i><b>Page</b></i>
1	Causes of anemia in chronic renal failure patients	7
2	Factors Associated with an Increase in CRP in Patients on Dialysis	10
3	Impact of Anemia in CKD	13
4	Potential causes of erythropoietin hyporesponsiveness	23
5	Common features of serum lipid/lipoprotein profile in predialysis CKD patients with or without nephrotic proteinuria and in ESRD patients treated with chronic hemodialysis or peritoneal dialysis	37
6	Common features of serum lipid/lipoprotein profile in predialysis CKD patients with or without nephrotic proteinuria and in ESRD patients treated with chronic hemodialysis or peritoneal dialysis	42
7	Comparison between the mean values of hematological markers before and after 3 months in group1 (statin users)	82
8	Comparison between mean values of biochemical markers before and after 3 months in group 1 (statin users)	83
9	Comparison between mean values of the hematological markers before and after 3 months in non statin group 2	87
10	Comparison between mean values of biochemical markers before and after 3 months in non statin group	88

### List of tables (Cont.)

<i>Table</i>	<i>Title</i>	<i>Page</i>
11	Comparison of mean values of changes between both studied groups before and after 3 months occurred in hematological markers	89
12	Comparison of mean values of changes between both studied groups occurred in biochemical markers	90
13	Percentage of significant changes occurred in hematological and biochemical markers of statin group after the 3 months	92
14	Correlation between EPO dose and hematological markers base on the change occurred in statin group	93
15	Correlation between EPO dose requirements change and biochemical markers based on the change occurred in statin group	94



## List of Figures

<b><i>Fig.</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
1	Mechanisms in anemia leading to myocardial damage in chronic kidney disease	15
2	Anemia Management in CKD	28
3	Major classes of lipoproteins with predominant= apoprotein components. Small, dense, low-density lipoprotein(LDL) and lipoprotein(a) [Lp(a)] may be more atherogenic	34
4	The possible mechanisms of uremic dyslipidemia	43
5	Essential steps of cholesterol biosynthesis	47
6	Mean values of EPO dose, serum iron and transferring saturation measured before and after 3 months in group1	84
7	Mean values of EPO dose, serum iron and transferring saturation measured before and after 3 months in group1	85
8	Mean values of LDL, HDL, cholesterol and triglycerides measured before and after 3 months in statin HD patients	86
9	Mean values of change in hemoglobin, albumin, transferrin saturation and CRP measured before and after 3 months in both studied groups	91
10	Mean values of change in, LDL, cholesterol, triglycerides and HDL measured before and after 3 months in both studied groups	91
11	Correlation between EPO change and Hb change in statin group	95



## **Introduction**

Anaemia of end-stage renal disease patients has been effectively treated with erythropoietin (EPO). EPO therapy reduced the need for blood transfusions and improved the quality of life in maintenance haemodialysis (HD) patients. (*NFK 2001*), EPO responsiveness in patients with chronic renal failure depends on the dose, the route and the frequency of administration (*Eschbachjw 2002*).

Factors that contribute to EPO hyporesponsiveness include iron deficiency, infections, inadequate dialysis, chronic blood loss, hyperparathyroidism, aluminum toxicity, malnutrition, vitamin deficiency, malignancy and others (*Drueke T 2002*).

Drugs (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers) have been identified as contributory factors to EPO resistance (*raoDS, et al 2003*). Inflammation has also been reported as a factor contributing to EPO hyporesponsiveness (*Gunell G, et al. 1999*).

C-reactive protein (CRP), an acute phase protein, is the most well-investigated representative marker of inflammation in the general population and in chronic kidney disease (CKD) patients (*Yeun JY, et al. 2000*) CRP predicts the risk of cardiovascular events and may play a role in the atherosclerotic process in general population (*Koenig W Loelh, Baumert 2004*). CRP also predicts mortality in HD patients, and high

levels of CRP have been associated with resistance to EPO therapy in HD patients, possibly by indicating the presence of some micro inflammation (*Locatelli F, et al. 2006*).

The prevalence of dyslipidemia in end-stage renal disease is greater than that in the general population (*Kasiske BL, et al. 2002*). Lipid abnormalities may result in atherosclerotic vascular disease and statin therapy could lower the risk of cardiovascular events by reducing plasma cholesterol and triglycerides both in general population and HD patients (*Seliger SL, et al 2002*). Moreover, statins seem to exert other pleiotropic effects on inflammation, the immune system and thrombosis (*Davignon J, et al. 2004*).

Statin may reduce CRP levels in the general population patients. (*Vernaglione Let al.2004*). It has also been suggested that statins by reducing CRP levels have a positive impact on EPO responsiveness (*Dornbrook-Lavender KA, et al 2005*).

## **Aim of the Study**

Evaluate the effect of statin therapy on Erythropoietin responsiveness in prevalent Haemodialysis patients.

## **Chapter I**

# **Anemia in CKD and Role of Erythropoietin**

Anemia of CKD is one of the first signs of kidney dysfunction, yet it often goes undetected because of its insidious onset. Anemia develops gradually as kidney function declines and the GFR drops to 70 ml/min in male patients and 50 ml/min in females. Epidemiologic data indicate that two-thirds of patients in the early stages of kidney failure are also anemic, with a hemoglobin level of less than 11 g/dl, yet only one-third of these patients have ever received erythropoietin stimulating agents (ESAs) to treat their anemia (*Taliercio, 2010*).

### **Definition of Anemia:-**

Anemia is defined as a decrease in the number of circulating red blood cells (RBCs), a reduction in the amount of Hb in the RBCs, or a combination of both. Although there are natural variations in laboratory values, and Hb varies by age and gender, the average normal ranges of Hb in adult men and women are as follows: 14 to 18 g/dl in males, and 12 to 16 g/dl in females (*Basile, 2007*).

Anemia in CKD, as defined by The National Kidney Foundation (NKF), is hemoglobin (Hb) concentration < 12 g/dl for women and < 13.5 g/dl for men. Conversely, the European Best Practices Guidelines for the Management of

Anemia in Patients with Chronic Renal Failure defines anemia according to age and sex. Anemia is defined as an Hb concentration of < 11.5 g/dl in women, < 13.5 g/dl in men  $\leq$  70 years of age, and < 12 g/dl in men > 70 years of age (*O'Mara, 2008*).

### **Prevalence of Anemia:-**

Anemia is very common in patients with chronic kidney disease and probably causes many of its symptoms. Physicians should start thinking about anemia when their patient's glomerular filtration rate (GFR) declines to 60 mL/minute/1.73 m<sup>2</sup> or less. In the third National Health and Nutrition Examination Survey, the prevalence of anemia in stage 3 chronic kidney disease (ie, a GFR of 30 to 59 ml/ minute/1.73 m<sup>2</sup>) was 5.2%, rising to 44.1% in stage 4, and becoming almost universal in stage 5. African Americans and patients with diabetes have even higher rates of anemia at each stage of kidney disease (*Nurko, 2006*).

### **How kidney failure leads to anemia?**

Insufficient erythropoietin production is the primary cause of anemia in patients with CKD. Various secondary causes can contribute to anemia, including a deficiency of iron, folate, or vitamin B12, gastrointestinal bleeding, severe hyperparathyroidism, inflammatory conditions and shortened red blood cell survival due to uremia. Deficiencies of folate and vitamin B12 cause macrocytic anemia. Elevated parathyroid hormone concentrations and acute and chronic